Chrysos Corporation reports a robust Q2 FY25 with a 12% quarter-on-quarter and 53% year-on-year revenue increase, driven by expanding international sales and rising sample volumes. The company secured two new contracts, boosting its PhotonAssay™ footprint and maintaining strong financial health.
Wellnex Life has negotiated a delayed and reduced-cost payment arrangement for its Pain Away acquisition, aligning with its upcoming London Stock Exchange dual listing plans. The move supports the company’s growth momentum following record revenues from Pain Away.
Hazer Group has successfully completed its Commercial Demonstration Plant program ahead of schedule, validating its methane pyrolysis technology and securing significant funding to accelerate commercialisation in 2025.
Spacetalk Limited reports a robust 12% increase in Annual Recurring Revenue to $11 million, driven by a 21% jump in paid mobile subscribers, signaling strong momentum and international ambitions.